Will FDA and DOJ Reassert Their Enforcement Muscle With Life Sciences in 2022? | Skadden, Arps, Slate, Meagher & Flom LLP
Takeaways - Despite predictions that the Biden administration would devote increased enforcement resources to the life sciences industry broadly, so far, the FDA and DOJ have focused...
Source: jdsupra.com